Hana Florian
AbbVie (United States)(US)
Publications by Year
Research Areas
Alzheimer's disease research and treatments, Dementia and Cognitive Impairment Research, Health Systems, Economic Evaluations, Quality of Life, Cholinesterase and Neurodegenerative Diseases, Parkinson's Disease Mechanisms and Treatments
Most-Cited Works
- A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia.(2008)
- → Preclinical and Clinical Development of ABBV-8E12, a Humanized Anti-Tau Antibody, for Treatment of Alzheimer's Disease and Other Tauopathies.(2017)136 cited
- → Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial(2021)134 cited
- → Tilavonemab in early Alzheimer’s disease: results from a phase 2, randomized, double-blind study(2023)121 cited
- → Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer’s Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study(2016)34 cited
- → Navitoclax safety, tolerability, and effect on biomarkers of senescence and neurodegeneration in aged nonhuman primates(2024)22 cited
- → Safety, tolerability and pharmacokinetics of the histamine H3 receptor antagonist, ABT‐288, in healthy young adults and elderly volunteers(2012)19 cited
- → The H3antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers(2013)17 cited
- → O1‐05‐02: EFFICACY AND SAFETY OF THE ALPHA7 AGONIST ABT‐126 AS A MONOTHERAPY TREATMENT IN MILD‐TO‐MODERATE ALZHEIMER'S DEMENTIA: RESULTS OF A PHASE 2B TRIAL(2014)11 cited
- → [O2–17–01]: RESULTS OF A PHASE 1, SINGLE ASCENDING DOSE, PLACEBO‐CONTROLLED STUDY OF ABBV‐8E12 IN PATIENTS WITH PROGRESSIVE SUPRANUCLEAR PALSY AND PHASE 2 STUDY DESIGN IN EARLY ALZHEIMER's DISEASE(2017)11 cited